About Fate Therapeutics, Inc.
https://www.fatetherapeutics.comFate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide.
CEO
Bahram Valamehr
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 59
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Wedbush
Outperform
Barclays
Overweight
Wells Fargo
Equal Weight
Baird
Neutral
Needham
Hold
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
REDMILE GROUP, LLC
Shares:12.87M
Value:$13.9M
BLACKROCK, INC.
Shares:10.68M
Value:$11.54M
BLACKROCK INC.
Shares:10.12M
Value:$10.93M
Summary
Showing Top 3 of 192
About Fate Therapeutics, Inc.
https://www.fatetherapeutics.comFate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $1.74M ▼ | $36.48M ▼ | $-32.25M ▲ | -1.85K% ▼ | $-0.27 ▲ | $-29.02M ▲ |
| Q2-2025 | $1.91M ▲ | $38.88M ▼ | $-34.07M ▲ | -1.79K% ▲ | $-0.29 ▲ | $-30.79M ▲ |
| Q1-2025 | $1.63M ▼ | $42.91M ▼ | $-37.62M ▲ | -2.31K% ▲ | $-0.32 ▲ | $-37.95M ▲ |
| Q4-2024 | $1.86M ▼ | $63.61M ▲ | $-52.15M ▼ | -2.8K% ▼ | $-0.44 ▼ | $-42.2M ▲ |
| Q3-2024 | $3.07M | $55.45M | $-47.68M | -1.55K% | $-0.4 | $-47.77M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $215.42M ▼ | $343.67M ▼ | $109.61M ▼ | $234.07M ▼ |
| Q2-2025 | $222.83M ▼ | $371.63M ▼ | $110.27M ▲ | $261.36M ▼ |
| Q1-2025 | $240.43M ▼ | $398.67M ▼ | $110.26M ▼ | $288.41M ▼ |
| Q4-2024 | $279.07M ▼ | $440.69M ▼ | $121.97M ▼ | $318.73M ▼ |
| Q3-2024 | $296.92M | $494.97M | $132.64M | $362.33M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-32.25M ▲ | $-24.37M ▲ | $21.27M ▲ | $2.48M ▲ | $-627K ▲ | $-26.58M ▼ |
| Q2-2025 | $-34.07M ▲ | $-24.59M ▲ | $19.59M ▼ | $1.32M ▲ | $-3.67M ▼ | $-25.95M ▲ |
| Q1-2025 | $-37.62M ▲ | $-33.81M ▼ | $42.67M ▲ | $0 ▼ | $8.86M ▲ | $-35.01M ▼ |
| Q4-2024 | $-52.15M ▼ | $-27.8M ▲ | $22.82M ▼ | $3.13M ▲ | $-1.85M ▼ | $-27.9M ▲ |
| Q3-2024 | $-47.68M | $-29.42M | $25.46M | $0 | $992K | $-29.91M |
Revenue by Products
| Product | Q1-2023 | Q2-2023 | Q3-2023 | Q4-2023 |
|---|---|---|---|---|
 Upfront Fee And Equity Premium | $30.00M ▲ | $30.00M ▲ | $30.00M ▲ | $0 ▼ |
CEO
Bahram Valamehr
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 59
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Wedbush
Outperform
Barclays
Overweight
Wells Fargo
Equal Weight
Baird
Neutral
Needham
Hold
Grade Summary
Showing Top 6 of 7
Price Target
Institutional Ownership
REDMILE GROUP, LLC
Shares:12.87M
Value:$13.9M
BLACKROCK, INC.
Shares:10.68M
Value:$11.54M
BLACKROCK INC.
Shares:10.12M
Value:$10.93M
Summary
Showing Top 3 of 192